Title: HERBAL FORMULATION FOR WOUND HEALING

Abstract: The present invention pertains to a herbal formulation with highly potent wound healing properties, in humans and animals. The composition consists of aqueous extracts of Azadirachta indica, in a mixture of natural oils along with herbs viz. Berberis aristata, Curcuma longa, Glycyrrhiza glabra, Jasminum officinale, Picrotoxina kurroo, Pongamia pinnata, Rubia cordifolia, Saussurea lappa, Terminalia chebula, Trichosanthes dioica, Capsicum and Stellata wild in well-defined ratios. The invention also includes a process for preparing the formulation by extracting the water-soluble components from bark of Azadirachta indica.
HERBAL FORMULATION FOR WOUND HEALING

The following specifications particularly describes the invention and the manner in which it has to be performed:
FIELD OF INVENTION

The present invention relates to the field of herbal formulations having therapeutic properties. More specifically, it relates to a herbal formulation having potent antimicrobial, anti fungal and wound healing properties, which is quite effective in curing external wounds of any nature in humans, especially non-healing wounds of diabetics and wounds referred to as 'bed sores'. The herbal formulation is also quite effective in treating wounds in animals.

BACKGROUND OF THE INVENTION

As is well-known in the prior art, usual methods for the cure of wounds whether in humans or animals, involve certain well-defined steps. These are curettage (removal of dead/infected tissues), disinfection (with disinfectants containing either iodine or hydrogen peroxide) and antibiotic therapy (either local or systemic, in form of powder, cream or spray). Lastly, to avoid hardening of the skin and crust formation, gauzes soaked in fatty humecants based on Vaseline, silicone oils or glycerol are applied. Dressing of the wound with sterile gauze is usually carried out not only to prevent exposure of the wound to infectious agents e.g. bacteria present in the environment, but also to soak exudations and secretions from the wound. These bandages need to be removed at regular intervals. In poor hygienic or environmental conditions e.g. those frequently present in developing countries, the wounds cannot be managed adequately and remain exposed to dust and environmental infestations which can contribute to important infections of the wound.

Despite efficacious anti-microbial treatment and improved supportive measures, wound treatment still poses immense challenges. Treatment and cure for invasive infections, blunt injuries, burns caused by electrical or chemical accidents, radiation burns and the like, is not very effective and leaves much to be desired. In fact, introduction of clinically effective anti-microbial agents has resulted in the rapid emergence of strains of bacteria resistant to such agents.

In countries with aging populations e.g the Unites States, leg ulcers in patients pose major challenges. An estimated 2 million workdays are lost in the US because of leg ulcers.
Apart from loss of man days, cost of treating these non-healing wounds can be tremendous. The prevalence of pressure ulcers (pressure sores or 'bed' sores) of the lower body in the elderly has been estimated to be 3-11%. The morbidity and mortality associated with pressure ulcers is significant. The death rate in patients with pressure ulcers is four fold greater than those without. In addition, septic elderly patients with pressure ulcers have a hospital mortality rate in excess of 50%. Treatment costs can be expensive owing to inclusion of intensive nursing care as well as adjunctive therapies e.g. anti pressure devices, protective dressings and skin treatments.

Wounds of diabetics are practically unmanageable and are usually regarded as ' incurable'. In fact, diabetes is an important underlying condition in leg ulcers. Various therapies for the treatment of leg ulcers e.g. multi-layer compression-bandage systems, topical recombinant human platelet derived growth factor, human skin equivalent for skin grafting etc. are available which may aid in wound healing. However, these therapies are expensive and may be cost prohibitive for many patients. Quite often inability to treat wounds leads to amputation of the infected limbs. Wound management in animals poses additional challenges. Unlike humans, chances of exposure of wounds to environmental infestations, in case of animals are much higher. Of particular concern are attacks by flies especially myiasigenic flies (sarcophagidae, calliphoridae) or any other flies (muscidae) which can aggravate wounds and lead to complications. To prevent infestations by flies, a common practice adopted in case of wounded animals is pouring creolina (mixture of phenols and tar) on the wounded area. This remedy though well-entrenched in animal husbandry, has serious limitations and disadvantages. Not only is it tissue damaging and toxic, but its 'insect protecting or repelling' action is very short-lived- barely half an hour! Another animal husbandry practice involves direct use of insecticides on the maggot infected wounds or sores. Apart from risk of acute or chronic intoxication of the animals, the practice poses environmental threat and also risk of contamination of the food chain, if the animals are involved in products for human consumption e.g. meat or milk. The present invention eliminates all such risks.

Wound healing and management, whether in humans or animals thus poses serious challenges. Existing therapies of modern science have limitations when it comes to treatment and cure of certain wounds. In animals, wounds and lesions pose practical
challenges especially under tropical conditions of high temperature and humidity when flies become very active. Such conditions also affect wound treatment in humans, especially in developing countries, where hygienic conditions are very often completely inadequate. The risk of complications due to parasites, bacteria etc. are a harsh reality, especially for weak and undernourished subjects, especially children.

The present invention provides a novel herbal composition comprising aqueous extracts of neem bark along with several herbs in a mixture of natural oils. The composition which is meant for external or topical application only, exhibits remarkable antibiotic and wound-healing properties. It is particularly effective in treating and curing wounds, which are regarded as 'incurable' in state of the art. The potency and powerful antimicrobial action of the herbal formulation is due to the synergistic action of the components, mainly plant extracts, present in it.

The present invention provides an effective and low cost method for treatment of wounds and sores.

PRIOR ART DISCUSSION

A number of herbal formulations for wound healing and injuries have been described in the prior art. US patent application no. 2006/0134229 discloses a herbal formulation consisting of the organic extract of the plant- Geum Japonicum Thunb variant. The invention is specifically directed for the cure of skeletal muscle injuries and soft tissue healing and not that of wounds.

PCT application no. WO2005/115090 A2 discloses a herbal composition having potent antimicrobial and wound healing properties. The composition contains extracts of only Ficus species along with Azadirachta indica, prepared by use of aqueous as well as organic solvents in admixture with pharmaceutically acceptable carriers, excipients and adjuvants. Use of bark of the respective plants is emphasized. No other component is added in the herbal composition in the described invention.
SUMMARY OF THE INVENTION

According to the present invention a novel herbal formulation is provided for external or topical application, for the treatment and cure of all types of wounds and lesions in humans and animals. The herbal formulation consists of aqueous extracts of neem bark, in a mixture of natural oils along with several herbs, in well-defined ratios. The composition exhibits remarkable efficacy in treating and curing wounds, which are regarded as 'incurable' in state of the art. The herbal formulation was arrived at by carrying out meticulous studies by the inventor, to identify the most effective and active combination of plant extracts in wound care.

OBJECTS OF THE INVENTION

It is a general objective of the invention to provide a novel herbal formulation for wound healing and its method of manufacture. Yet another objective is to provide a herbal formulation which provides an inexpensive alternative wound healing therapy, which does not have undesirable side-effects. Another objective of the present invention is to disclose a herbal formulation which is easy to manufacture.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention describes a herbal wound healing formulation which is used to treat different types of wounds/injuries in humans and animals and helps in preventing amputations.

Another embodiment of the invention is that the formulation improves blood flow and has immuno-modulatory properties in addition to being anti-bacterial, anti-fungal, anti inflammatory and analgesic. The formulation is also useful for treating infections and chronic non-healing wounds like diabetic foot ulcer, dry and wet gangrene, venous ulcer, varicose veins, war wounds, burn wounds, post operative situation and the like.

Another embodiment of the invention is that the formulation acts by applying it topically e.g skin applications and/or externally (eye/ear/nasal drops, gynaecological applications etc).

Another embodiment of the invention is a composition of the formulation composed of
an aqueous extract, a oil-herbs mix along with other adjuncts.

a) The aqueous part consists of an aqueous extract of the bark of *Azadirachta indica* in the range 4-7%, preferably 6% in water.

b) The oil-herbs mix consists of a mixture of four oils viz. castor, mustard, coconut and black sesame in equal ratios, along with twelve herbs in the range of 0.5-4% preferably 1% viz. *Berberis aristata* or *Berberis vulgaris*, *Curcuma longa* (6-9%, preferably 7%), *Glycyrrhiza glabra*, *Jasminum officinale*, *Picrorhiza kurrooa*, *Pongamia pinnata*, *Rubia cordifolia*, *Saussurea lappa*, *Terminalia chebula*, *Trichosanthes dioica* (6-9%, preferably 7%), *Capsicum* and *Stellata wild*.

c) Suitable adjuncts include thickening agents, preservatives, coloring agents, fragrances and opacifiers

The appropriate part of the herb used in the formulation is given below:

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Scientific Name</th>
<th>Part Used in formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><em>Azadirachta indica</em></td>
<td>Bark</td>
</tr>
<tr>
<td>2.</td>
<td><em>Berberis vulgaris</em></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td><em>Berberis aristata</em></td>
<td>Root</td>
</tr>
<tr>
<td>3.</td>
<td><em>Curcuma longa</em></td>
<td>Whole root</td>
</tr>
<tr>
<td>4.</td>
<td><em>Glycyrrhiza glabra</em></td>
<td>Stem</td>
</tr>
<tr>
<td>5.</td>
<td><em>Jasminum officinale</em></td>
<td>Whole plant comprising of stem, leaves and flowers</td>
</tr>
<tr>
<td>6.</td>
<td><em>Picrorhiza kurrooa</em></td>
<td>Rhizome (stem)</td>
</tr>
<tr>
<td>7.</td>
<td><em>Pongamia pinnata</em></td>
<td>Seeds or leaves</td>
</tr>
<tr>
<td>8.</td>
<td><em>Rubia cordifolia</em></td>
<td>Stem</td>
</tr>
<tr>
<td>9.</td>
<td><em>Saussurea lappa</em></td>
<td>Rhizome</td>
</tr>
<tr>
<td>10.</td>
<td><em>Terminalia chebula</em></td>
<td>Fruit</td>
</tr>
<tr>
<td>11.</td>
<td><em>Trichosanthes dioica</em></td>
<td>Fruit or Leaves</td>
</tr>
<tr>
<td>12.</td>
<td><em>Capsicum</em></td>
<td>Fruit</td>
</tr>
<tr>
<td>13.</td>
<td><em>Stellata wild</em></td>
<td>Flower</td>
</tr>
</tbody>
</table>

It will be appreciated by those skilled in the art that the above approximate weight percents are dependent generally on the expected potencies of the individual
components, whereby the relative weight percents will vary sometimes substantially from the above individual amounts. It will be within the skilled person’s knowledge with this disclosure that the objects of the present invention require the inclusion of each of the components in relative approximate weight percents above.

The easy commercial availability of all the ingredients, the ease of manufacturing of the extracts and the finished product provides a cheap and effective alternative wound healing therapy, which does not have undesirable side-effects.

Example 1

Preparation of aqueous extract:
The bark of *Azadirachta indica* is weighed, then thoroughly washed in cold water to remove any dirt, soil, undesirable contaminants etc. Distilled or de-ionized water in a 16:1 dry weight ratio to the herb is then added and allowed to soak overnight. The mixture is then boiled vigorously to reduce the volume of water to 1/4\textsuperscript{th} the original quantity. The extract is then filtered to remove the unwanted insoluble material. The extract obtained is the aqueous extract and is reddish brown.

Preparation of the oil mix:
The twelve herbs as listed above in dry form are weighed in appropriate quantities and then thoroughly washed in cold water. These are then dried and powdered. The dry weight percentage of each herbs is 1% except for two herbs, *Curcuma longa* and *Trichosanthes dioica* where dry weight percentage is 7% . Four oils as mentioned above, are taken in equal ratios, mixed in a container and dried herbs in powdered form, added to the oil mix.

Preparation of the formulation:
The aqueous extract is added to the oil mix and heated till all the water has evaporated. This step results in the entry of thermostable, water soluble compounds derived from the bark of *Azadirachta indica* into an oil mix phase, along with extracts of other herbs. To the hot formulation are added thickeners, present in amounts anywhere from about 1-7% by weight, preferably 2%. In the present formulation, bee-wax is used as the thickener. To protect the formulation from any harmful growths, suitable preservatives have to be added. These include alkyl esters of p-hydroxybenzoic acid,
hydantoin derivatives, propionate salts, potassium sorbate, sodium benzoate. The use
of copper sulphate at low concentrations, is also well-documented in ancient Indian
medical texts (Ayurveda). In the present formulation, copper sulphate at 0.25% 
concentration is used. The formulation is allowed to cool and filtered using appropriate
filters available commercially. The final formulation is yellowish-green.

Example 2

The clean dried bark of *Azadirachta indica* is weighed and soaked overnight in
distilled or de-ionized water in a 16:1 dry weight ratio. The mixture is then boiled to
reduce the volume of water to 1/4th the original quantity. The extract is then filtered to
remove the unwanted insoluble material. The extract obtained is the aqueous extract
and is reddish brown.

**Preparation of the oil mix:**
The clean and dried herbs as listed above in specified weight ratios are powdered.
Alcohol extract of all the herbs is prepared which is then de-colorized using activated
charcoal and then filtered. This filtrate is mixed in four oils taken in equal ratios and
mixed in a container

**Preparation of the formulation:**
The aqueous extract is added to the oil mix and heated till all the water and alcohol
evaporated. To the hot formulation are added bee wax as thickener in an amount of 2%
by weight and copper sulphate at 0.25% concentration as preservative. The formulation
is allowed to cool and filtered using appropriate filters available commercially. The
final formulation is almost colourless.

Additional herbs e.g. *Sumplocos racemosa* and *Ichnicarpus frutescens* along with minor
adjunct components may also be incorporated into preferred embodiments of the
formulation. The adjunct components include coloring agents, fragrances and opacifiers.
The effect on skin may also be enhanced by adding various vitamins e.g. A, C and B and
nutrients which also serve as antioxidants to help prevent the emollient degradation of the
formulation.
We claim:

1. A wound healing formulation comprising of:
   a.) an effective amount of extract of Azadirachta indica
   b.) an effective amount of extract of herbs selected from the group comprising of Berberis aristata, Curcuma longa, Glycyrrhiza glabra, Jasminum officinale, Picrorhiza kurrooa, Pongamia pinnata, Rubia cordifolia, Saussurea lappa, Terminalia chebula, Trichosanthes diocia, Capsicum, Stellata wild and oil mix adjuncts such as thickening agents, preservatives, coloring agents, decolorizing agents, fragrances, opacifiers and vitamins, wherein the extracts of Azadirachta indica are aqueous while those of the herbs are oil or alcohol extracts, present together in the formulation in synergistic ratios.

2. The formulation of claim 1 where in:
   a.) the appropriate part of Azadirachta indica used in preparation of the aqueous extract is bark
   b.) the appropriate parts of the herbs used in the formulation are root of Berberis aristata or Berberis vulgaris, stem of Glycyrrhiza glabra, whole plant consisting of stem, leaves and flowers of Jasminum officinale, rhizome of Picrorhiza kurrooa, seeds or leaves of Pongamia pinnata, stem of Rubia cordifolia, rhizome of Saussurea lappa, fruit of Terminalia chebula, fruits or leaves of Trichosanthes diocia, fruit of Capsicum and flowers of Stellata wild in a mixture of four oils viz. castor oil, mustard oil, coconut oil and black sesame.
   c) the adjuncts used in the preparation are copper sulphate as preservative, bee wax as thickening agent, de colorizing agents such as activated charcoal and or Fuller's earth, Calcium -D- Saccharate, Serolite, Bentonite or Magnesium oxide.

3. The formulation of claim 2 where in:
   a.) concentration of aqueous extracts of Azadirachta indica in the formulation ranges from 4-7%.
   b.) concentration of other natural herbs in the formulation ranges from 0.5%- 4% for Berberis aristata or Berberis vulgaris, Glycyrrhiza glabra, Jasminum officinale, Picrorhiza
kurrooa, Pongamia pinnata, Rubia cordifolia, Saussurea lappa, Terminalia chebula, Trichosanthes dioica, Capsicum and Stellata wild, from 6%- 9% for Curcuma longa and Trichosanthes dioica and all the oils are present in equal ratios.

c.) concentration of copper sulphate in the formulation ranges from 0.1-0.5% and that of bee wax ranges from 1-7% by weight.

4. A process for preparing the formulation of claim 1, which comprises the steps of:

- Preparing aqueous extract by taking water and dry bark of Azadirachta indica in ratio of 16 parts water to 1 part of the bark, boiling the same to reduce the water to 1/4th the original concentration and filtering the same.

- Preparing oil herbs mixture by mixing four oils viz. castor, mustard, coconut and black sesame in equal ratios to each other and adding appropriate quantities of dry powdered parts/alcohol extract of the herbs Berberis aristata, Curcuma longa, Glycyrrhiza glabra, Jasminum officinale, Picrorhiza kurrooa, Pongamia pinnata, Rubia cordifolia, Saussurea lappa, Terminalia chebula, Trichosanthes dioica, Capsicum and Stellata wild to the oil mixture.

- Preparing formulation by adding aqueous extract of Azadirachta indica to oil-herb mixture in ratio of 4:1 and boiling till the water evaporates completely, followed by addition of adjunct components such as thickeners, preservatives deodorizing agents, coloring agents, fragrances, opacifiers and vitamins.

5. The formulation according to claim 1 which prevents amputations.

6. The formulation for wound healing substantially as described herein before.
# INTERNATIONAL SEARCH REPORT

**INTERNATIONAL APPLICATION NO**

PCT/IN2007/000557

## A. CLASSIFICATION OF SUBJECT MATTER

**INV. A61K36/58**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 5 693 327 A (SHAH ELADEVI [GB]) 2 December 1997 (1997-12-02) claims 1,2</td>
<td>1-6</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of Box C.

**Date of the actual completion of the international search**

5 March 2008

**Date of mailing of the international search report**

14/04/2008

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epcnl, Fax: (+31-70) 340-2016

Authorized officer

Fayos, Cécile

---

* Special categories of cited documents:
  
  "A" document defining the general state of the art which is not considered to be of particular relevance
  
  "E" earlier document but published on or after the international filing date
  
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  
  "O" document referring to an oral disclosure, use, exhibition or other means
  
  "P" document published prior to the international filing date but later than the priority date claimed

* "X" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Z" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* "X" document member of the same patent family
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>FR 2 101 244 A (KEIMDIAET GMBH [DE])</td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td>31 March 1972 (1972-03-31) the whole document</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>GB 2 314 269 A (M S RAPTAKOS BRETT &amp; CO LTD [IN]) 24 December 1997 (1997-12-24)</td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>ZA 9 802 679 A (AMAR INTERNAT PVT LTD L)</td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td>30 September 1998 (1998-09-30) the whole document</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>ZA 9 803 753 A (AMAR INTERNAT PVT LTD L)</td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td>29 November 1999 (1999-11-29) the whole document</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>DE 100 19 670 A1 (PALERMO DIEGO [DE])</td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td>31 October 2001 (2001-10-31) the whole document</td>
<td></td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>US 5693327 A</td>
<td>02-12-1997</td>
<td>NONE</td>
</tr>
<tr>
<td>FR 2101244 A</td>
<td>31-03-1972</td>
<td>DE 2038827 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 1314136 A</td>
</tr>
<tr>
<td>GB 2314269 A</td>
<td>24-12-1997</td>
<td>IN 180999 A1</td>
</tr>
<tr>
<td>ZA 9802679 A</td>
<td>30-09-1998</td>
<td>NONE</td>
</tr>
<tr>
<td>ZA 9803753 A</td>
<td>29-11-1999</td>
<td>NONE</td>
</tr>
<tr>
<td>DE 10019670 A1</td>
<td>31-10-2001</td>
<td>NONE</td>
</tr>
<tr>
<td>HU 9904431 A1</td>
<td></td>
<td>NONE</td>
</tr>
</tbody>
</table>